This proposal describes our efforts toward the synthesis of peptide mimetic molecules against chronic myelogenous leukemia (CML). In collaboration with the Deisseroth laboratory, we will target the p210/bcrabl protein kinase. Specifically, we are interested in the design of small-molecules that will specifically bind to and potentially inhibit the proliferation of myelogenous leukemia cells in vivo. Researchers on this project will synthesize a number of small-molecules, based on a general-binding scaffold, which will be tested for binding to and inhibition of p210/bcrabl. The library proposed here has been designed on the principle of a general- binding scaffold, and involves the random presentation of amino acid side chains, or """"""""natural functionality"""""""", around a rigid molecular scaffold. The philosophy behind a general-binding scaffold is that nature's functionality can be radially displayed, preferable in a random and diverse fashion, to mimic both peptide and signaling molecules which may bind to and affect a protein of interest. We propose that the functionality displayed ont the molecular scaffold will have the ability to sample many local conformations,t hereby increasing the changes of identifying a small molecule inhibitor. Each of the compounds synthesized will be forwarded to the Deisseroth Laboratory for in vitro binding constants and in vivo activity. Lead compounds from these assays will then be further subjected to design and randomization in an effort to improve inhibition and gain beneficial pharmacophoric properties needed for their development as chemotherapeutic drug candidates.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA049639-10
Application #
6203150
Study Section
Project Start
1999-07-12
Project End
2000-01-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
10
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Ruvolo, Peter P; Ruvolo, Vivian R; Burks, Jared K et al. (2018) Role of MSC-derived galectin 3 in the AML microenvironment. Biochim Biophys Acta Mol Cell Res 1865:959-969
Cortes, Jorge E; Gambacorti-Passerini, Carlo; Deininger, Michael W et al. (2018) Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol 36:231-237
Sasaki, Koji; Kantarjian, Hagop; O'Brien, Susan et al. (2018) Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer 124:1160-1168
Gambacorti-Passerini, Carlo; Cortes, Jorge E; Lipton, Jeff H et al. (2018) Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study. Haematologica 103:1298-1307
Boddu, Prajwal; Shah, Abdul Rashid; Borthakur, Gautam et al. (2018) Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma 59:1312-1322
Kornblau, Steven M; Ruvolo, Peter P; Wang, Rui-Yu et al. (2018) Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survival. Haematologica 103:810-821
Zhang, Weiguo; Ly, Charlie; Ishizawa, Jo et al. (2018) Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial. Haematologica 103:1642-1653
Alhuraiji, Ahmad; Kantarjian, Hagop; Boddu, Prajwal et al. (2018) Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol 93:84-90
Ishizawa, Jo; Nakamaru, Kenji; Seki, Takahiko et al. (2018) Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Res 78:2721-2731
Boddu, Prajwal; Benton, Christopher B; Wang, Wei et al. (2018) Erythroleukemia-historical perspectives and recent advances in diagnosis and management. Blood Rev 32:96-105

Showing the most recent 10 out of 375 publications